Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant axitinib plus avelumab for localized renal cell carcinoma
2024-515825-27-00Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab and axitinib in clear cell renal cell carcinoma (ccRCC), sponsored by Netherlands Cancer Institute. Primary endpoint: Rate of partial remission following neoadjuvant axitinib and avelumab. Planned start Jul 2024; status: authorised.
02
Drugs
avelumabaxitinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2024-515825-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515825-27-00.